Menu Search
Equities

Olympus Corp

7733:TYO

Olympus Corp

Actions
Health CareMedical Equipment and Services
  • Price (JPY)2,655.00
  • Today's Change77.50 / 3.01%
  • Shares traded1.30m
  • 1 Year change+27.52%
  • Beta0.9184
Data delayed at least 20 minutes, as of Sep 19 2024 03:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform8
Hold3
Sell0
Strong Sell0

Share price forecast in JPY

The 12 analysts offering 12 month price targets for Olympus Corp have a median target of 2,945.00, with a high estimate of 3,200.00 and a low estimate of 2,000.00. The median estimate represents a 14.26% increase from the last price of 2,577.50.
High24.2%3,200.00
Med14.3%2,945.00
Low-22.4%2,000.00

Dividends in JPY

In 2024, Olympus Corp reported a dividend of 18.00 JPY, which represents a 12.50% increase over last year. The 15 analysts covering the company expect dividends of 20.34 JPY for the upcoming fiscal year, an increase of 13.01%.
Div growth (TTM)12.50%
More ▼

Earnings history & estimates in JPY

On Aug 07, 2024, Olympus Corp reported 1st quarter 2025 earnings of 12.51 per share.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+17.22%
Olympus Corp reported annual 2024 earnings of 199.91 per share on May 10, 2024.
Average growth rate+206.32%
More ▼

Revenue history & estimates in JPY

Olympus Corporation had 1st quarter 2025 revenues of 234.82m. This bettered the 234.22m consensus of the 7 analysts covering the company. This was 13.05% above the prior year's 1st quarter results.
Average growth rate+3.44%
Olympus Corporation had revenues for the full year 2024 of 936.21m. This was 6.16% above the prior year's results.
Average growth rate+4.55%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.